Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH. Wang F, et al. Among authors: yuan xl. Ann Oncol. 2019 Sep 1;30(9):1479-1486. doi: 10.1093/annonc/mdz197. Ann Oncol. 2019. PMID: 31236579 Free PMC article. Clinical Trial.
[Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)].
Wang X, Liu Y, Huang JX, Lu P, Ba Y, Wu L, Bai YX, Zhang S, Feng JF, Cheng Y, Li J, Wen L, Yuan XL, Ma CW, Hu CH, Fan QX, Xu BH, Huang J. Wang X, et al. Among authors: yuan xl. Zhonghua Zhong Liu Za Zhi. 2021 Nov 23;43(11):1177-1182. doi: 10.3760/cma.j.cn112152-20191022-00678. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34794220 Clinical Trial. Chinese.
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C. Shi Y, et al. Cancer Commun (Lond). 2021 Sep;41(9):889-903. doi: 10.1002/cac2.12179. Epub 2021 Jun 29. Cancer Commun (Lond). 2021. PMID: 34184418 Free PMC article. Clinical Trial.
[The analysis of prognosis-associated factors in adults with acute promyelocytic leukemia].
Ma RJ, Zhu ZM, Yuan XL, Jiang L, Yang SW, Yang J, Guo JM, Shi J, Lei PC, Zhang L, Shang BJ, Sun K, Zhai YP, Li W, Zhang Y. Ma RJ, et al. Among authors: yuan xl. Zhonghua Xue Ye Xue Za Zhi. 2017 Jul 14;38(7):592-596. doi: 10.3760/cma.j.issn.0253-2727.2017.07.007. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28810326 Free PMC article. Chinese.
[Efficacy of combination of ATRA, ATO and anthracyclines induction therapy in patients with acute promyelocytic leukemia].
Ma RJ, Zhu ZM, Yuan XL, Jiang L, Yang SW, Yang J, Guo JM, Zhang L, Lei PC, Wang Z, Zang YZ, Chen YQ, Wang TB, Kong D, Sun K, Zhang Y. Ma RJ, et al. Among authors: yuan xl. Zhonghua Xue Ye Xue Za Zhi. 2017 Jun 14;38(6):523-527. doi: 10.3760/cma.j.issn.0253-2727.2017.06.011. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28655097 Free PMC article. Chinese.
262 results